Tocilizumab in the treatment of severe and refractory parenchymal neuro-Behçet's syndrome: case series and literature review.

导出 OA

翻译打印收藏纠错

第一作者： Jinjing,Liu

第一单位： Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

作者： Jinjing,Liu ^[1] ; Dong,Yan ^[2] ; Zhimian,Wang ^[1] ; Yunjiao,Yang ^[1] ; Shangzhu,Zhang ^[1] ; Di,Wu ^[1] ; Lingyi,Peng ^[1] ; Zhichun,Liu ^[2] ; Wenjie,Zheng ^[3]

作者单位： Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China. ^[1] Department of Rheumatology and Immunology, The Second Affiliated Hospital of Soochow University, Suzhou, China. ^[2] Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Key Laboratory of Rheumatology and Clinical Rheumatology, Ministry of Education, National Clinical Research Center for Dermatologic and Immunologic Diseases, No. 1 Shuafuyuan, Dongcheng District, Beijing, 100730, China. ^[3]

关键词 Beh?et’s syndrome neurological involvement tocilizumab

DOI 10.1177/1759720X20971908

PMID 33240406

发布时间 2024-08-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交